Published 4 days ago

Keymed Biosciences Announces Approval of Stapokibart For the Treatment of Seasonal Allergic Rhinitis

Summary by Laotian Times

CHENGDU, China, Feb. 8, 2025 /PRNewswire/ — KeyMed Biosciences (HKEX: 02162) today announced the National Medical Products Administration (the “NMPA“) of China has recently approved the supplemental New Drug Application (the “sNDA“) of Stapokibart (anti-IL-4Rα monoclonal antibody, trade name: Kangyueda (康悦达), for the treatment of seasonal allergic rhinitis. The approval is based on a multi-center, […]

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources0

Leaning Left0Leaning Right0Center0Last Updated3 days agoBias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Keymed Biosciences Announces Approval of Stapokibart For the Treatment of Seasonal Allergic Rhinitis

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics